Wainwright C L, Parratt J R
Eur J Pharmacol. 1987 Jan 20;133(3):257-64. doi: 10.1016/0014-2999(87)90021-5.
The effects of the thromboxane antagonist BM 13.177 (5 mg kg-1 + 0.15 mg kg-1 min-1) was investigated on the ventricular arrhythmias that result from coronary artery occlusion and reperfusion in anaesthetised open-chest greyhounds. BM 13.177 markedly reduced the severity and incidence of arrhythmias resulting from ischaemia; the number of ventricular ectopic beats was reduced from 1,084 +/- 159 (in controls) to 544 +/- 179 (in dogs given BM 13.177) and the incidences of ventricular tachycardia (VT) and ventricular fibrillation (VF) were reduced from 86 to 22% and from 30 to 10% respectively. Following reperfusion the incidence of VF was 86% in controls and 44% in dogs given BM 13.177. Thus the total incidence of VF during the combined ischaemia-reperfusion insult was significantly reduced by treatment with BM 13.177 from 90% (in control dogs) to 50%. These results lend further support to the hypothesis that thromboxane is involved in the genesis of arrhythmias and that blockade of thromboxane receptors may be a suitable approach to antiarrhythmic therapy under conditions of ischaemia and reperfusion.
研究了血栓素拮抗剂BM 13.177（5毫克/千克 + 0.15毫克/千克·分钟）对麻醉开胸灵缇犬冠状动脉闭塞和再灌注所致室性心律失常的影响。BM 13.177显著降低了缺血所致心律失常的严重程度和发生率；室性早搏数量从1084±159（对照组）降至544±179（给予BM 13.177的犬），室性心动过速（VT）和室颤（VF）的发生率分别从86%降至22%和从30%降至10%。再灌注后，对照组VF发生率为86%，给予BM 13.177的犬为44%。因此，在缺血 - 再灌注损伤联合过程中，BM 13.177治疗使VF总发生率从90%（对照犬）显著降至50%。这些结果进一步支持了以下假说：血栓素参与心律失常的发生，并且在缺血和再灌注条件下，阻断血栓素受体可能是一种合适的抗心律失常治疗方法。
